November 1, 2005
Originally Published MDDI November 2005
Abbott Diagnostics' newly approved carotid artery stent is the second such product approved for U.S. use.
Carotid artery stenting, one of MD&DI's Top 10 Technologies in 2005, has a new U.S. player.
Abbott Diagnostics in September received FDA approval for its Xact Carotid Stent and Emboshield Embolic Protection System. It is the second such product approved for U.S. use. Guidant Corp. (Indianapolis) received clearance for its stent offering in 2004.
The procedure is for patients with carotid artery disease who are at high risk for stroke. It is a less-invasive alternative to carotid endarterectomy, the surgical removal of plaque, which remains the standard of care.
Today's U.S. carotid stent market is estimated at $60 million. But Abbott and other players estimate it could increase to as much as $1 billion if clinical data support treating a broader patient population.
Copyright ©2005 Medical Device & Diagnostic Industry
About the Author(s)
You May Also Like